The TREAT-NMD care and trial site registry: An online registry to facilitate clinical research for neuromuscular diseases

Orphanet Journal of Rare Diseases

Volumn 8, Issue 1, 2013, Pages

  Rodger, Sunil ^a   Lochmüller, Hanns ^a   Tassoni, Adrian ^b   Gramsch, Kathrin ^b   König, Kirsten ^b   Bushby, Kate ^a   Straub, Volker ^a   Korinthenberg, Rudolf ^b   Kirschner, Janbernd ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Care sites; CARE NMD; Centres of expertise; Clinical trials; CTSR; ERN; Rare diseases; Reference networks; Registries; Trial sites

Indexed keywords

ADULTHOOD; ARTICLE; BIBLIOGRAPHIC DATABASE; CARE AND TRIAL SITE REGISTRY; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DUCHENNE MUSCULAR DYSTROPHY; GERMANY; GOOD CLINICAL PRACTICE; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HUMAN; LIMB GIRDLE MUSCULAR DYSTROPHY; MAJOR CLINICAL STUDY; MEDICAL SPECIALIST; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MUSCULAR DYSTROPHY; MYOTONIC DYSTROPHY; NEUROMUSCULAR DISEASE; ONLINE SYSTEM; PATIENT CARE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); SPINAL MUSCULAR ATROPHY; UNITED KINGDOM; UNITED STATES;

FEMALE; HUMANS; MALE; NEUROMUSCULAR DISEASES; REGISTRIES;

EID: 84885975020     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-8-171     Document Type: Article

References (24)

1. COM(2008) 679 Final: Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions on Rare Diseases: Europe's Challenges. [ http://ec.europa.eu/health/ph-threats/non-com/docs/rare-com-en.pdf ]
2. TREAT-NMD. [ http://www.treat-nmd.eu/ ]
3. EPIRARE survey on activities and needs of rare disease registries in the European Union. Taruscio D, Gainotti S, Vittozzi L, Bianchi F, Ensini M, Posada M, Orphanet J Rare Dis 2012 7 22 10.1186/1750-1172-7-S2-A22
4. Rare disease registries in Europe, January 2013, Orphanet report series. [ http://www.orpha.net/orphacom/cahiers/docs/GB/Registries.pdf ]
5. The Parkinson Study Group. [ http://www.parkinson-study-group.org ]
6. European Cystic Fibrosis Society. [ http://www.ecfs.eu ]
7. European Huntington's Disease Network. [ http://www.euro-hd.net ]
8. Dubowitz Neuromuscular Centre: Conditions we treat. [ http://www.gosh.nhs.uk/health-professionals/clinical-specialties/ neuromuscular-information-for-health-professionals/conditions-we-treat/ ]
9. EUCERD Recommendations on Quality Criteria for Centres of Expertise for Rare Diseases in Member States, 24th October 2011. [ http://www.EUCERD.eu/ upload/file/EUCERDRecommendationCE.pdf ]
10. Muscular Dystrophy Campaign. [ http://www.muscular-dystrophy.org ]
11. CARE-NMD. [ http://www.care-nmd.eu/ ]
12. Care and Trial Site Registry (CTSR). [ https://zks-internet.ukl.uni- freiburg.de/ctsr ]
13. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, et al. Lancet Neurol 2010 9 77 93 10.1016/S1474-4422(09)70271-6 19945913
14. Transition to adulthood for young men with Duchenne muscular dystrophy: research from the UK. Abbott D, Carpenter J, Bushby K, Neuromuscul Disord 2012 22 445 446 10.1016/j.nmd.2012.02.004 22425491
15. North Star Clinical Network. [ http://www.muscular-dystrophy.org/how-we- help-you/for-professionals/clinical-databases ]
16. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, et al. Lancet Neurol 2010 9 177 189 10.1016/S1474-4422(09)70272-8 19945914
17. British Myology Society. [ http://www.cnmd.ac.uk/partners/BMS ]
18. The TREAT-NMD Duchenne muscular dystrophy registries: conception, design, and utilization by industry and academia. Bladen CL, Rafferty K, Straub V, Monges S, Moresco A, Dawkins H, Roy A, Chamova T, Guergueltcheva V, Korngut L, et al. Hum Mutat 2013 34 1449 1457 10.1002/humu.22390 23913485
19. Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase. Tuffery-Giraud S, Beroud C, Leturcq F, Yaou RB, Hamroun D, Michel-Calemard L, Moizard MP, Bernard R, Cossee M, Boisseau P, et al. Hum Mutat 2009 30 934 945 10.1002/humu.20976 19367636
20. Orphanet expert centres database. [ http://www.orpha.net/consor/cgi-bin/ Clinics-Search.php?lng?=?EN ]
21. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen G-J, den Dunnen JT, Hum Mutat 2009 30 293 299 10.1002/humu.20918 19156838
22. Prevalence of genetic muscle disease in northern england: in-depth analysis of a muscle clinic population. Norwood FLM, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V, Brain 2009 132 3175 3186 10.1093/brain/awp236 19767415
23. Can outcomes in Duchenne muscular dystrophy be improved by public reporting of data? Scully MA, Cwik VA, Marshall BC, Ciafaloni E, Wolff JM, Getchius TS, Griggs RC, Neurol 2013 80 583 589 10.1212/WNL.0b013e318282334e
24. NeurOmics. [ http://www.rd-neuromics.eu/ ]